jama glp-1 Data Brief: receptor agonist use among US adults with type 2 diabetes nearly doubled between 2019 and 2022, primarily driven by semaglutide and dulaglutide. https://ja.ma/3XDwnr1 From JAMA: #GLP-1 receptor agonist

When considering the overall expense, its important to weigh the frequency of treatments with the kind of results youre looking for

According to the 2024 National Epidemiological Survey on Overweight and Obesity, around 18% of the French population, approximately 10 million people, are obese

Nature 498 (7452), 99103

Furthermore, long-term fracture risk, bone microarchitecture changes, and implant survival in GLP-1 agonist users remain poorly studied

It has a high affinity to GLP-1R, strongly activating the GLP-1R Gs cAMP pathway without inducing measurable -arrestin recruitment signaling, which indicates it is a fully biased agonist

Lately theres been a wave of products like Inno Shred GLP-1 that market themselves as weight-loss game changers, but they dont have semaglutide, tirzepatide, or any other GLP-1 meds inside